Skip to content

Tomáš Páleníček

Charles University, National Institute of Mental Health

72 papers in the library · 2,946 citations · publishing 2007-2026

Papers

Sort Most recent Most cited

Psychedelics in the treatment of cluster headaches

Klinická farmakologie a farmacie April 29, 2025 Michal Židó, Tomáš Páleníček, Ivana Štětkářová

Psychedelika jsou psychoaktivn ltky, kter bezprostedn po uit typicky vyvolvaj zmny vnmn, mylen, emotivity a kognitivnch proces. V posledn dob se intenzivn zkoum jejich antidepresivn a anxiolytick efekt. Hlavn vhodou tchto ltek je rychl nstup inku s dlouhodobm inkem po podn jedn i jen nkolika mlo dvek. Maj tak dobr bezpenostn profil. Dal vyuit mohou mt tyto ltky v lb chronickch bolest u...

DOI: 10.36290/far.2025.021 (opens in new tab) Full text (opens in new tab) Headaches Cluster headache Cluster spacecraft Migraine +1

The acute effects of methoxphenidine on behaviour and pharmacokinetics profile in animal model.

Progress in Neuro-Psychopharmacology and Biological Psychiatry March 20, 2025 Kristýna Štefková-mazochová, Hynek Danda, Vladimír Mazoch et al. 3 citations

Methoxphenidine (MXP) is classified as a new psychoactive substance that has recently emerged on the illicit drug market. Understanding the pharmacological and behavioural profiles of newly emerging drugs is essential for a better understanding of their psychotropic effects and potential toxicity. Therefore, in this study, we investigated a broad range of effects of acute MXP administration:...

DOI: 10.1016/j.pnpbp.2025.111285 (opens in new tab) Full text (opens in new tab) Methoxphenidine Pharmacokinetics Systemic toxicity Wistar rats +7

The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression.

Journal of Affective Disorders March 1, 2025 Guy M. Goodwin, Scott T Aaronson, Oscar Alvarez et al. 35 citations

To determine the relationships between psilocybin dose, psychedelic experiences, and therapeutic outcome in treatment-resistant depression. For treatment-resistant depression, 233 participants received a single dose of 25, 10, or 1 mg of COMP360 psilocybin (a proprietary, pharmaceutical-grade synthesized psilocybin formulation, developed by the sponsor, Compass Pathfinder Ltd.) with...

Serotonergic Psychedelics Rapidly Modulate Evoked Glutamate Release in Cultured Cortical Neurons

Journal of Neurochemistry February 28, 2025 Aneta Petrušková, Debarpan Guhathakurta, Enes Yağız Akdaş et al. 8 citations

ABSTRACT The serotonergic psychedelics psilocybin, LSD and DMT hold great promise for the development of new treatments for psychiatric conditions such as major depressive disorder, addiction and end‐of‐life anxiety. Previous studies in both animals and humans have confirmed the effects of these drugs on neuronal activity and plasticity. However, the understanding of the mechanisms of action of...

Exploring Psilocybe cubensis Strains: Cultivation Techniques, Psychoactive Compounds, Genetics and Research Gaps

Journal of Fungi January 28, 2025 Eyal Kurzbaum, Tomáš Páleníček, Amiel Shrchaton et al. 11 citations

Psilocybe cubensis, a widely recognized psychoactive mushroom species, has played a significant role in both historical and modern therapeutic practices. This review explores the complex interplay between genetic diversity, strain variability and environmental factors that shape the biosynthesis of key psychoactive compounds, including psilocybin and psilocin. With many strains exhibiting...

Exploring 5-MeO-DMT as a pharmacological model for deconstructed consciousness.

Neuroscience of Consciousness 2025 Christopher Timmermann, James W. Sanders, David Reydellet et al. 19 citations

5-MeO-DMT is a short-acting psychedelic that is anecdotally reported to induce a radical disruption of the self and a paradoxical quality of aroused, waking awareness that is nevertheless devoid of any specific perceptual contents. Here, we conducted an exploratory observational study of the phenomenological and neuronal effects of this compound. We collected micro-phenomenological interviews,...

DOI: 10.1093/nc/niaf007 (opens in new tab) Full text (opens in new tab) Serotonin EEG Neurophenomenology Consciousness-research +3

Mescaline-induced behavioral alterations are mediated by 5-HT2A and 5-HT2C receptors in rats.

Pharmacology, Biochemistry, and Behavior December 1, 2024 Lucie Olejníková-Ladislavová, Michaela Fujáková-Lipski, Klára Šíchová et al. 5 citations

Mescaline is a classical psychedelic compound with a phenylethylamine structure that primarily acts on serotonin 5-HT2A/C receptors, but also binds to 5-HT1A and 5-HT2B receptors. Despite being the first psychedelic ever isolated and synthesized, the precise role of different serotonin receptor subtypes in its behavioral pharmacology is not fully understood. In this study, we aimed to...

DOI: 10.1016/j.pbb.2024.173903 (opens in new tab) Full text (opens in new tab) Mescaline Psychedelics hallucinogens Locomotor activity Sensorimotor gating +6

Hexahydrocannabinol (HHC): pharmacokinetics, systemic toxicity, and acute behavioural effects in Wistar rats.

October 2, 2024 Klára Šíchová, Barbara Mallarino, Lucie Janeckova et al.

Background and purpose: Hexahydrocannabinol (HHC) is a novel psychoactive substance that has gained attention due to its psychotropic effects and temporary legal status. It is widely abused in several EU and US countries, where it serves as a legal and easily accessible alternative to ∆ 9 -tetrahydrocannabinol (∆ 9 -THC). Despite its widespread use, few studies have examined its in vivo effects...

DOI: 10.22541/au.172786658.80817958/v1 (opens in new tab) Pharmacokinetics Toxicity Pharmacology

Psilocybin alters brain activity related to sensory and cognitive processing in a time-dependent manner

medRxiv September 11, 2024 Marek Nikolič, Pedro A. M. Mediano, Tom Froese et al. 6 citations preprint

Abstract Psilocybin is a classic psychedelic and a novel treatment for mood disorders. Psilocybin induces dose-dependent transient (4-6 hours) usually pleasant changes in perception, cognition, and emotion by non-selectively agonizing the 5-HT 2A receptors and negatively regulating serotonin reuptake, and long-term positive antidepressant effect on mood and well-being. Long-term effects are...

DOI: 10.1101/2024.09.09.24313316 (opens in new tab) Psilocybin Cognition Sensory system Sensory processing +2

Behavioral pharmacology of mescaline - the role of serotonin 5-HT2A, 5-HT2B, 5-HT2C and 5-HT1A receptors

bioRxiv Preprint Server August 28, 2024 Lucie Olejníková-Ladislavová, Michaela Fujáková-Lipski, Klára Šíchová et al. preprint

Rationale Mescaline is a classical psychedelic compound with a phenylethylamine structure that primarily acts on serotonin 5-HT2A/C receptors, but also binds to 5-HT1A and 5-HT2B receptors. Despite being the first psychedelic ever isolated and synthesized, the precise role of different serotonin receptor subtypes in its behavioral pharmacology is not fully understood.

DOES THE PHENOMENOLOGY OF THE PSILOCYBIN EXPERIENCE PREDICT LONG-TERM EFFECTS ON MOOD AND WELL-BEING IN HEALTHY VOLUNTEERS?

IBRO Neuroscience Reports November 6, 2023 Tomáš Páleníček, Tereza Klučková, Marek Nikolič et al.

INTRODUCTION: The mechanisms by which the psychedelic drug psilocybin, a novel rapid-acting antidepressant, improves depressive symptoms are still unclear. One candidate mechanism is the impact of the phenomenology of the psychedelic experience, with positive phenomenology hypothesised to be associated with positive long-term outcomes and fearful phenomenology hypothesised to be associated with...

MODULATION OF SYNAPTIC FUNCTION AND NEURONAL NETWORK ACTIVITY BY SEROTONERGIC PSYCHEDELICS

IBRO Neuroscience Reports October 1, 2023 Aneta Petrušková, Eva‐maria Weiss, Debarpan Guhathakurta et al.

Serotonergic psychedelics (SP) such as psilocybin, LSD or DMT pose significant potential for development of new strategies in treating neuropsychiatric disorders including major depression disorder, post-traumatic stress disorder and addiction. To bring these substances to clinical application, however, better understanding of the mechanisms behind their effects on many levels, including...

CROSS-SPECIES EVIDENCE FOR PSILOCIN-INDUCED VISUAL HALLUCINATIONS: RATS PERCEIVE QUALITATIVELY SIMILAR CHANGES AS HUMANS

IBRO Neuroscience Reports October 1, 2023 Čestmír Vejmola, Kateřina Syrová, Klára Šíchová et al.

GABAB receptors are the metabotropic GABA neurotransmitter receptors in the central nervous system constituting a fundamental part of the inhibitory modulation mechanism.These receptors are heterodimers composed of GABAB1 and GABAB2 which function is modulated by the potassium channel tetramerization domain proteins (KCTD) from clade F (KCTD16; KCTD12 and KCTD8).In our experiments we explored...

DOI: 10.1016/j.ibneur.2023.08.1471 (opens in new tab) Visual hallucination Cognitive psychology

Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life

Journal of Affective Disorders February 3, 2023 Guy M. Goodwin, Scott T Aaronson, Oscar Alvarez et al. 168 citations

Three weeks after dosing, psilocybin 25 mg and, to a lesser degree, 10 mg improved measures of patient-reported depression severity, anxiety, affect, and functioning. These results extend the primary findings from the largest randomised clinical trial of psilocybin for TRD to examine other outcomes that are of importance to patients.

DOI: 10.1016/j.jad.2023.01.108 (opens in new tab) Anxiety Psilocybin Antidepressant Patient-reported outcomes +5

Acute pharmacological profile of 2C-B-Fly-NBOMe in male Wistar rats-pharmacokinetics, effects on behaviour and thermoregulation.

Frontiers in Pharmacology 2023 Kateřina Syrová, Klára Šíchová, Hynek Danda et al. 4 citations

Introduction: N-2-methoxy-benzylated ("NBOMe") analogues of phenethylamine are a group of new psychoactive substances (NPS) with reported strong psychedelic effects in sub-milligram doses linked to a number of severe intoxications, including fatal ones. In our present work, we provide a detailed investigation of pharmacokinetics and acute behavioural effects of 2C-B-Fly-NBOMe...

DOI: 10.3389/fphar.2023.1120419 (opens in new tab) Full text (opens in new tab) 2c-b-fly-nbome Nbome series New psychoactive substance Pharmacokinetics +10

Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.

New England Journal of Medicine November 3, 2022 Guy M. Goodwin, Scott T Aaronson, Oscar Alvarez et al. 1,095 citations

Psilocybin is being studied for use in treatment-resistant depression. In this phase 2 double-blind trial, we randomly assigned adults with treatment-resistant depression to receive a single dose of a proprietary, synthetic formulation of psilocybin at a dose of 25 mg, 10 mg, or 1 mg (control), along with psychological support. The primary end point was the change from baseline to week 3 in the...

DOI: 10.1056/nejmoa2206443 (opens in new tab) Full text (opens in new tab) Treatment-resistant depression Psilocybin therapy Psychedelic medicine Mental health research +1

Pharmacokinetics, systemic toxicity, thermoregulation and acute behavioural effects of 25CN‐NBOMe

Addiction Biology August 4, 2022 Klára Šíchová, Kateřina Syrová, Edita Kofroňová et al. 8 citations

agonists containing substances emerging on the illicit drug market as a replacement for N,N-diethyllysergamide (LSD). Despite the increasing use of NBOMes for diagnostic, research and recreational purposes, only a limited number of studies have focussed on their in vivo effect. Here, we investigated pharmacokinetics, systemic toxicity, thermoregulation in individually and group-housed animals,...

DOI: 10.1111/adb.13216 (opens in new tab) Thermoregulation Pharmacology Acute toxicity Pharmacokinetics

Psilocybin—Mediated Attenuation of Gamma Band Auditory Steady-State Responses (ASSR) Is Driven by the Intensity of Cognitive and Emotional Domains of Psychedelic Experience

Journal of Personalized Medicine June 19, 2022 Vojtěch Viktorin, Inga Griškova-bulanova, Aleksandras Voicikas et al. 19 citations

Psilocybin is a classical serotoninergic psychedelic that induces cognitive disruptions similar to psychosis. Gamma activity is affected in psychosis and is tightly related to cognitive processing. The 40 Hz auditory steady-state responses (ASSR) are frequently used as indicators to test the ability to generate gamma activity. Based on previous literature, we studied the impact of psilocybin on...

Pharmacokinetic, pharmacodynamic, and behavioural studies of deschloroketamine in Wistar rats.

British Journal of Pharmacology 2022 Kristýna Štefková-mazochová, Hynek Danda, Wim Dehaen et al. 13 citations

Deschloroketamine (DCK), a structural analogue of ketamine, has recently emerged on the illicit drug market as a recreational drug with a modestly long duration of action. Despite it being widely used by recreational users, no systematic research on its effects has been performed to date. Pharmacokinetics, acute effects, and addictive potential in a series of behavioural tests in Wistar rats...

DOI: 10.1111/bph.15680 (opens in new tab) Full text (opens in new tab) Nmda receptor Deschloroketamine Enantiomers Locomotion +2

Psilocin, LSD, mescaline, and DOB all induce broadband desynchronization of EEG and disconnection in rats with robust translational validity

Translational Psychiatry October 2, 2021 Čestmír Vejmola, Filip Tylš, Václava Piorecká et al. 41 citations

Abstract Serotonergic psychedelics are recently gaining a lot of attention as a potential treatment of several neuropsychiatric disorders. Broadband desynchronization of EEG activity and disconnection in humans have been repeatedly shown; however, translational data from animals are completely lacking. Therefore, the main aim of our study was to assess the effects of tryptamine and...

The Effects of Daytime Psilocybin Administration on Sleep: Implications for Antidepressant Action

Frontiers in Pharmacology December 3, 2020 Daniela Dudysová, Karolína Janků, Michal Šmotek et al. 37 citations

Serotonergic agonist psilocybin is a psychedelic with antidepressant potential. Sleep may interact with psilocybin’s antidepressant properties like other antidepressant drugs via induction of neuroplasticity. The main aim of the study was to evaluate the effect of psilocybin on sleep architecture on the night after psilocybin administration. Regarding the potential antidepressant properties, we...

DOI: 10.3389/fphar.2020.602590 (opens in new tab) Psilocybin Antidepressant Slow-wave sleep Sleep spindle +4

Naphyrone (naphthylpyrovalerone): Pharmacokinetics, behavioural effects and thermoregulation in Wistar rats

Addiction Biology May 7, 2020 Nikola Pinterová, Rachel R. Horsley, Hynek Danda et al. 13 citations

Naphthylpyrovalerone (naphyrone) is a pyrovalerone cathinone that potently inhibits monoamine transporters and provides stimulatory-entactogenic effects. Little is known about the safety of naphyrone or its effects in vivo, and more research is needed to acquire knowledge about its fundamental effects on physiology and behaviour. Our objective was to investigate naphyrone's pharmacokinetics,...

DOI: 10.1111/adb.12906 (opens in new tab) Pharmacokinetics Pharmacology Open field In vivo +4

A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding

European Neuropsychopharmacology March 4, 2020 M. Madsen, Patrick M. Fisher, Dea Siggaard Stenbæk et al. 189 citations

A single dose of the serotonin 2A receptor (5-HT2AR) agonist psilocybin can have long-lasting beneficial effects on mood, personality, and potentially on mindfulness, but underlying mechanisms are unknown. Here, we for the first time conduct a study that assesses psilocybin effects on cerebral 5-HT2AR binding with [11C]Cimbi-36 positron emission tomography (PET) imaging and on personality and...

Cannabis-induced altered states of consciousness are associated with specific dynamic brain connectivity states

Journal of Psychopharmacology June 3, 2019 Yuliya Zaytseva, Jiřı́ Horáček, Jaroslav Hlinka et al. 25 citations

BACKGROUND: Cannabis, and specifically one of its active compounds delta-9-tetrahydrocannabinol in recreational doses, has a variety of effects on cognitive processes. Most studies employ resting state functional magnetic resonance imaging techniques to assess the stationary effects of cannabis and to-date one report addressed the impact of delta-9-tetrahydrocannabinol on the dynamics of...

DOI: 10.1177/0269881119849814 (opens in new tab) Cannabis Precuneus Delta-9-tetrahydrocannabinol Resting State FMRI +3

A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms.

Psychopharmacology April 13, 2019 Malin V. Uthaug, R. Lancelotta, Kim van Oorsouw et al. 198 citations

Background: 5-methoxy-N,N-dimethyltryptamine (hereinafter referred to as 5-MeO-DMT) is a psychedelic substance found in the secretion from the parotoid glands of the Bufo alvarius toad. Inhalation of vapor from toad secretion containing 5-MeO-DMT has become popular in naturalistic settings as a treatment of mental health problems or as a means for spiritual exploration. However, knowledge of...

DOI: 10.1007/s00213-019-05236-w (opens in new tab) Full text (opens in new tab) Mental health Psychological health Emotional well-being Mental wellness +25